Quantcast

Latest Andrew Witty Stories

2010-02-04 07:17:00

LONDON, February 4 /PRNewswire-FirstCall/ -- GlaxoSmithKline today said it had posted a strong performance in a challenging year with a return to sales growth for the first time since 2007. In an interview on http://www.cantos.com CEO Andrew Witty also announced a reduction in the investment into treatments for pain and depression and a restructuring of R&D. He said: "Now obviously I don't like to see anybody leave the organisation or there to be any job losses. But the...

2010-02-01 13:58:00

PHILADELPHIA, Feb. 1 /PRNewswire-FirstCall/ -- On Thursday, February 4, 2010, GlaxoSmithKline plc will announce its full year financial results for the year ended December 31, 2009. It is anticipated that the announcement will be released to the London Stock Exchange at approximately 7:00am Eastern Standard Time (EST) and available at www.gsk.com. Following the announcement, Andrew Witty, Chief Executive Officer, and Julian Heslop, Chief Financial Officer, will hold a briefing meeting for...

c8f1ae939bccd1b0847bad30b1e4e8a81
2010-01-20 15:30:51

A UK newspaper report showed that a British drug maker GlaxoSmithKline (GSK) is set to make thousands of chemical compounds that have the potential to cure malaria available for research, AFP reported. "Multinational drug companies must balance social responsibility with their need to make profits to please shareholders," said GSK chief executive Andrew Witty, during an interview with the Guardian on Wednesday. He said firms had an imperative to earn the trust of society, not just by meeting...

2010-01-20 08:09:00

PHILADELPHIA and LONDON, Jan. 20 /PRNewswire-FirstCall/ -- 'Open Lab' established with $8m seed funding for new research 13,500 malaria compounds to be made freely available New collaborations to share intellectual property for neglected tropical diseases Pledge to create sustainable pricing model for world's most advanced malaria candidate vaccine GSK African Malaria Partnership awards four new grants worth $2.5m Andrew Witty, Chief Executive of GlaxoSmithKline (NYSE: GSK), today...

2009-07-16 15:38:00

PHILADELPHIA, July 16 /PRNewswire-FirstCall/ -- On Wednesday, July 22nd, GlaxoSmithKline plc (NYSE: GSK) will announce its second quarter financial results for the three months ended June 30, 2009. It is anticipated that the announcement will be released to the London Stock Exchange at approximately 7:00 AM EDT. Following the announcement, Andrew Witty, Chief Executive Officer, Julian Heslop, Chief Financial Officer and Moncef Slaoui, Chairman R&D will hold a briefing meeting for...

2009-04-21 12:22:00

PHILADELPHIA, April 21 /PRNewswire-FirstCall/ -- On Wednesday, April 22, 2009 GlaxoSmithKline plc (NYSE: GSK) will announce its first quarter financial results for the three months ended March 31, 2009. It is anticipated that the announcement will be released to the London Stock Exchange at approximately 7:00 AM EDT. At 8:30 AM EDTAndrew Witty, Chief Executive Officer, and Julian Heslop, Chief Financial Officer will hold a briefing meeting for analysts and investors. A webcast will begin...

2009-04-20 10:23:47

British pharmaceutical giant GlaxoSmithKline said Monday it agreed to purchase skin-products producer Stiefel Laboratories for $2.9 billion. The deal includes the assumption of $400 million of Stiefel's debt, but will add a robust development pipeline to GlaxoSmithKline's product line, the company said in a statement. The deal also includes a potential $300 million cash payment depending on future performance. The addition of Stiefel's broad portfolio will provide immediate new revenue flows...

2009-04-20 06:00:00

Stiefel, the world's largest independent dermatology company, acquired by GSK in deal valued at up to $3.6 billion New global business will have combined revenues of approximately $1.5 billion and robust new product pipeline Significant step forward to grow and diversify GSK's business, providing immediate new revenue and synergy opportunities LONDON, April 20 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc (NYSE: GSK) and Stiefel Laboratories Inc. today announced that they have signed an...

2009-04-16 06:50:00

LONDON, April 16 /PRNewswire-FirstCall/ -- Pharmaceutical companies GlaxoSmithKline and Pfizer today announced an "innovative agreement" to pool their HIV assets creating a new world-leading, specialist HIV company. The deal will see the drug giants combine their existing HIV product and their pipelines with GSK holding 85% of the company and Pfizer 15%. The deal will be marginally dilutive to GSK earnings in the first two years but in a video interview Group CEO Andrew Witty...

2009-04-16 06:01:00

- Creates a new focused HIV business with the independence and sustainability to deliver significant improvements in treatment, access and shareholder value - Renews focus on HIV with industry-leading pipeline to deliver more new HIV treatments - Equity split of 85% GSK and 15% Pfizer LONDON and PHILADELPHIA, April 16 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc (NYSE: GSK) and Pfizer Inc (NYSE: PFE) today announced they have entered into an agreement to create a new world-leading HIV...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related